La Jolla Pharmaceutical Company Competitors, Revenue, Alternatives and Pricing

Claim your profile


Total Funding:$22.9M
Lead Investor(s):N/A

Estimated Revenue & Financials

  • La Jolla Pharmaceutical Company's total funding is $22.9M.

Employee Data

  • La Jolla Pharmaceutical Company has 249 Employees.(?)
  • La Jolla Pharmaceutical Company currently has 1 job openings.

La Jolla Pharmaceutical Company (LJPC) is a biopharmaceutical company that is focused on the research and development of highly specific therapeutics for the treatment of certain life-threatening antibody-mediated diseases. These diseases, including autoimmune conditions such as lupus and antibody-mediated stroke, are caused by abnormal B cell production of antibodies that attack healthy tissues. The Company\'s drug candidates, called Toleragens, are designed to treat the underlying cause of many antibody-mediated diseases without the severe, adverse side effects common to other treatments. The Company is analyzing data from a Phase III clinical trial of its lupus drug candidate, LJP 394, and its clinical drug candidate for the treatment of antibody-mediated thrombosis, known as LJP 1082, is currently being evaluated in toxicology studies that are required prior to the initiation of clinical trials.